Proteome Sciences Key Figures| Key Figures | | (at previous day's close) |
| Market Cap. | 11.03 | m |
| Shares In Issue | 294.65 | m |
| Prev. Close | 3.75 | |
| PE Ratio | 187.25 | |
| Dividend Yield | - | % |
| EPS - basic | 0.02 | p |
| Dividend PS | - | p |
| Dividend Cover | - | |
| Cash Flow PS | 0.27 | p |
| Return On Equity (ROE) | - | % |
| Operating Margin | 2.30 | % |
| PEG Factor | -2.34 | |
| EPS Growth Rate | -80.00 | % |
| Dividends PS Growth Rate | - | % |
| Dívida Líquida | 10.43 | m |
| Gross Gearing | 127.63 | % |
| Quick Assets | 3.47 | m |
| Net Working Capital | -7.16 | m |
| Intangibles / Fixed Assets | 76.87 | % |
| Turnover PS | 1.74 | p |
| Pre-Tax Profit PS | 0.04 | p |
| Retained Profit PS | 0.02 | p |
| Cash PS | 0.81 | p |
| Net Cash PS | -3.17 | p |
| Net Tangible Asset Value PS * | -2.37 | p |
| Net Asset Value PS | -0.94 | p |
| Spread | 0.49 (12.28%) | |
| * Calculation based on Ordinary Capital figure as contained in last annual report, and the most recent shares in issue figure. Therefore the ratio might be exposed to inaccuracies. |
|
Proteome Sciences Balance Sheet
 Share Price Performance| Share Price Performance | | Sample Period † | MAX | MIN | | 1 Semana | 3.75 | 3.75 |
| 4 Semanas | 3.90 | 3.60 |
| 12 Semanas | 4.00 | 3.35 |
| 1 Ano | 6.20 | 3.31 |
Share Price Chart (5 years)| Share Price Chart (5 years) |  |
|
Proteome Sciences Historic Returns| %1$s Historic Returns | | Período † | Abertura | VAB | % | Abertura Média | Vol Diário Médio [m] | Volume [m] | VWAP | | 1 Semana | 3.75 | - | - | 3.75 | 0.25 | | 3.75 |
| 4 Semanas | 3.70 | 0.04 | 1.22 | 3.60 | 0.13 | | 3.74 |
| 12 Semanas | 3.85 | -0.11 | -2.73 | 3.35 | 0.10 | | 3.70 |
| 26 Semanas | 4.65 | -0.91 | -19.46 | 3.31 | 0.21 | | 3.88 |
| 1 Ano | 6.00 | -2.26 | -37.58 | 3.31 | 0.23 | | 4.61 |
| 3 Anos | 3.70 | 0.04 | 1.22 | 2.35 | 0.41 | | 4.61 |
| 5 Anos | 3.73 | 0.02 | 0.54 | 2.22 | 0.35 | | 4.25 |
| † periods calculated are whole weeks rather than calendar months | |
|
Proteome Sciences Key Management Ratios
|
Proteome Sciences Investment Ratios| %1$s Investment Ratios | | (Market value analysis) at previous day's close |
| PQ Ratio | 66.04 | |
| PE Ratio | 187.25 | |
| Tobin's Q Ratio | 1.15 | |
| Tobin's Q Ratio (excl. intangibles) | 2.26 | |
| Dividend Yield | - | % |
| Market-to-Book Ratio | -3.98 | |
| Price-to-Pre-Tax Profit PS | 93.51 | |
| Price-to-Retained Profit PS | 153.26 | |
| Price-to-Cash Flow PS | 13.91 | |
| Price-to-Sales PS | 2.15 | |
| Price-to-Net Tangible Asset Value PS | -1.58 | |
| Price-to-Cash PS | 4.62 | |
| Net Working Capital PS | -2.43 | |
| Price Pct to Working Capital PS | -1.54 | % |
| Earnings Yield | 0.53 | % |
| Average PE | 116.70 | |
| Years in average | 3 | |
| PE to PE average | 160.45 | % |
|
Proteome Sciences Financial Ratios| %1$s Financial Ratios | | (Leverage Ratios) |
| Debt Ratio | -65.77 | % |
| Debt-to-Equity Ratio | -0.40 | |
| Debt-to-Equity Ratio (excl. Intgbl) | -0.16 | |
| Debt-to-Equity Market Value | 0.10 | |
| Net Gearing | 103.86 | % |
| Net Gearing (excl. Intangibles) | 179.05 | % |
| Gross Gearing | 127.63 | % |
| Gross Gearing (excl. Intangibles) | 220.01 | % |
| Gearing Under 1 Year | 116.67 | % |
| Gearing Under 1 Year (excl. Intgbl) | 201.12 | % |
| Assets/Equity | -3.62 | |
| Cash/Equity | -86.02 | |
| (Liquidity Ratios) |
| Net Working Capital to Total Assets | -71.29 | % |
| Current Ratio | 0.39 | |
| Quick Ratio (Acid Test) | 0.30 | |
| Liquidity Ratio | 0.20 | |
| Cash & Equiv/Current Assets | 52.37 | % |
| (Solvency Ratios) |
| Enterprise Value | 9.75 | m |
| CFO/Sales | 0.15 | |
| CFO/Attributable Profit | 11.01 | |
| CFO/Assets | 0.08 | |
| CFO/Debt | 0.06 | |
| Total Debt/Equity Market Value | 1.16 | |
| Total Debt/Sales | 2.50 | |
| Total Debt/Pre-Tax Profit | 108.64 | |
| Total Debt | 12.82 | m |
| Total Debt/Net Current Assets | -1.79 | % |
| (Dodds - Graham Ratios) | | |
| 3 yr Compound Earnings Growth | - | % |
| 5 yr Compound Earnings Growth | - | % |
| 10 yr Compound Earnings Growth | - | % |
| Earn drops > 5% in 10yrs | 10 | |
| Beta coefficients | | Beta (60-Mnth) | Beta (36-Mnth) | | 0.0006 | 0.0011 |
|
Proteome Sciences Operating Ratios| %1$s Operating Ratios | | (Profitability Ratios) |
| Return On Capital Employed (ROCE) | - | % |
| Return On Assets (ROA) | 0.75 | % |
| Net Profit Margin | 1.40 | % |
| Assets Turnover | 0.54 | |
| Return On Equity (ROE) | - | % |
| Return On Investment (ROI) | -3.17 | % |
| Dividend Payout Ratio | - | % |
| Plowback Ratio | 100.00 | % |
| Growth from Plowback Ratio | - | % |
| Net Income Of Revenues | 1.40 | % |
| (Asset Utilisation Multiples) |
| Shareholders Equity Turnover | -1.67 | |
| Fixed Assets Turnover | 0.96 | |
| Current Assets Turnover | 1.22 | |
| Net Working Capital Turnover | | |
| Inventory Turnover | 5.22 | |
| (Other Operating Ratios) |
| Total Assets-to-Sales | 1.87 | |
| Debtors-to-Sales | 18.24 | % |
| Debt Collection Period | 66.57 | Dias |
|
Proteome Sciences Dividends
|
|
Proteome Sciences Fundamentals |
| Profit and Loss Account | | | 31 Dez 2018 (GBP) | | 31 Dez 2019 (GBP) | | 31 Dez 2020 (GBP) | | 31 Dez 2021 (GBP) | |
| turnover | 3.41 | 100.00% | | 4.66 | 100.00% | | 4.75 | 100.00% | | 5.13 | 100.00% | m |
| pre tax profit | -1.66 | -48.67% | | -0.04 | -0.77% | | 0.25 | 5.15% | | 0.12 | 2.30% | m |
| attributable profit | -1.31 | -38.52% | | 0.15 | 3.20% | | 0.30 | 6.21% | | 0.07 | 1.40% | m |
| retained profit | -1.31 | -38.52% | | 0.15 | 3.20% | | 0.30 | 6.21% | | 0.07 | 1.40% | m |
| eps - basic (p) | -0.44 | | | 0.05 | | | 0.10 | | | 0.02 | | |
| eps - diluted (p) | -0.44 | | | 0.05 | | | 0.10 | | | 0.02 | | |
| dividends per share | - | | | - | | | - | | | - | | |
| | | | | | | | | | | | |
|
Proteome Sciences Balance Sheet| Balance Sheet | | | 31 Dez 2018 (GBP) | | 31 Dez 2019 (GBP) | | 31 Dez 2020 (GBP) | | 31 Dez 2021 (GBP) | |
 |   | |   | |   | |   | |
|
| | 31 Dez 2018 (GBP) | | 31 Dez 2019 (GBP) | | 31 Dez 2020 (GBP) | | 31 Dez 2021 (GBP) | |
| ASSETS | | | | | | | | | | | | |
 fixed assets | 0.06 | 0.80% | | 0.08 | 0.90% | | 0.06 | 0.64% | | 1.27 | 12.63% | m |
 intangibles | 4.22 | 60.03% | | 4.80 | 57.40% | | 5.16 | 56.74% | | 4.22 | 41.99% | m |
| fixed investments | - | -% | | 1.33 | 15.92% | | - | -% | | - | -% | m |
 current assets - other | - | -% | | - | -% | | - | -% | | - | -% | m |
| stocks | 1.15 | 16.32% | | 0.87 | 10.42% | | 0.88 | 9.66% | | 1.09 | 10.83% | m |
| debtors | 0.65 | 9.22% | | 0.49 | 5.81% | | 0.79 | 8.67% | | 1.08 | 10.78% | m |
 cash & securities | 0.96 | 13.63% | | 0.80 | 9.56% | | 2.21 | 24.30% | | 2.39 | 23.76% | m |
|
| TOTAL | 7.03 | 100% | | 8.36 | 100% | | 9.09 | 100% | | 10.05 | 100% | m |
|
| LIABILITIES | | | | | | | | | | | | |
 creditors - short | 10.50 | 149.45% | | 11.61 | 138.86% | | 11.96 | 131.52% | | 11.72 | 116.67% | m |
 creditors - long | 0.34 | 4.88% | | 0.40 | 4.82% | | 0.49 | 5.41% | | 1.10 | 10.96% | m |
| creditors - other | - | -% | | - | -% | | - | -% | | - | -% | m |
| subordinated loans | - | -% | | - | -% | | - | -% | | - | -% | m |
| insurance funds | - | -% | | - | -% | | - | -% | | - | -% | m |
|
| TOTAL | 10.85 | 154.33% | | 12.01 | 143.68% | | 12.45 | 136.93% | | 12.82 | 127.63% | m |
|
| EQUITY | | | | | | | | | | | | |
 ord cap, reserves | -3.82 | -54.33% | | -3.65 | -43.68% | | -3.36 | -36.93% | | -2.78 | -27.63% | m |
| prefs, minorities | - | -% | | - | -% | | - | -% | | - | -% | m |
|
| TOTAL | -3.82 | -54.33% | | -3.65 | -43.68% | | -3.36 | -36.93% | | -2.78 | -27.63% | m |
|
| OTHER | | | | | | | | | | | | |
| NAV Basic | - | | | - | | | - | | | - | | |
| NAV Diluted | - | | | - | | | - | | | - | | |
|
Proteome Sciences Cash Flow Statement| %1$s Cash Flow Statement | | 31 Dez 2018 (GBP) | | 31 Dez 2019 (GBP) | | 31 Dez 2020 (GBP) | | 31 Dez 2021 (GBP) | |
| Operating CF | -0.50 | | 0.02 | | 1.58 | | 0.79 | m |
| Pre-Financing CF | -0.51 | | -0.04 | | 1.57 | | 0.59 | m |
| Retained CF | 0.03 | | -0.10 | | 1.42 | | 0.19 | m |
| | | | | | | | |
|
Proteome Sciences Brokers
|
| |
| |
| |
| |
